Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin: 2014-2025

Historic EBT Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -49.67%.

  • Viridian Therapeutics, Inc.\DE's EBT Margin rose 8889684.00% to -49.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -427.30%, marking a year-over-year increase of 8463528.00%. This contributed to the annual value of -89,387.09% for FY2024, which is 1367562.00% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its EBT Margin stood at -49.67% for Q3 2025, which was up 99.96% from -134,313.33% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's EBT Margin's 5-year high stood at -49.67% during Q3 2025, with a 5-year trough of -134,313.33% in Q2 2025.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median EBT Margin value was -88,946.51% (recorded in 2024), while the average stood at -83,417.42%.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's EBT Margin slumped by 6,495,647bps in 2023 and then spiked by 8,889,684bps in 2025.
  • Viridian Therapeutics, Inc.\DE's EBT Margin (Quarterly) stood at -13,526.17% in 2021, then slumped by 3,007,859bps to -43,604.76% in 2022, then plummeted by 4,925,635bps to -92,861.11% in 2023, then plummeted by 1,794,861bps to -110,809.72% in 2024, then surged by 8,889,684bps to -49.67% in 2025.
  • Its EBT Margin stands at -49.67% for Q3 2025, versus -134,313.33% for Q2 2025 and -120,711.11% for Q1 2025.